These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 20731657)

  • 1. Presence of tissue transglutaminase in granular endoplasmic reticulum is characteristic of melanized neurons in Parkinson's disease brain.
    Wilhelmus MM; Verhaar R; Andringa G; Bol JG; Cras P; Shan L; Hoozemans JJ; Drukarch B
    Brain Pathol; 2011 Mar; 21(2):130-9. PubMed ID: 20731657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increase in endoplasmic reticulum-associated tissue transglutaminase and enzymatic activation in a cellular model of Parkinson's disease.
    Verhaar R; Drukarch B; Bol JG; Jongenelen CA; Musters RJ; Wilhelmus MM
    Neurobiol Dis; 2012 Mar; 45(3):839-50. PubMed ID: 22051113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease.
    Andringa G; Lam KY; Chegary M; Wang X; Chase TN; Bennett MC
    FASEB J; 2004 May; 18(7):932-4. PubMed ID: 15001552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of enzyme activity inhibits tissue transglutaminase-mediated transamidation of α-synuclein in a cellular model of Parkinson's disease.
    Verhaar R; Jongenelen CA; Gerard M; Baekelandt V; Van Dam AM; Wilhelmus MM; Drukarch B
    Neurochem Int; 2011 Jun; 58(7):785-93. PubMed ID: 21440023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue transglutaminase modulates alpha-synuclein oligomerization.
    Segers-Nolten IM; Wilhelmus MM; Veldhuis G; van Rooijen BD; Drukarch B; Subramaniam V
    Protein Sci; 2008 Aug; 17(8):1395-402. PubMed ID: 18505736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue transglutaminase cross-links beclin 1 and regulates autophagy in MPP⁺-treated human SH-SY5Y cells.
    Verhaar R; Drukarch B; Bol JG; Jongenelen CA; Wilhelmus MM
    Neurochem Int; 2013 Mar; 62(4):486-91. PubMed ID: 23380076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissecting the mechanisms of tissue transglutaminase-induced cross-linking of alpha-synuclein: implications for the pathogenesis of Parkinson disease.
    Schmid AW; Chiappe D; Pignat V; Grimminger V; Hang I; Moniatte M; Lashuel HA
    J Biol Chem; 2009 May; 284(19):13128-42. PubMed ID: 19164286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the unfolded protein response in Parkinson's disease.
    Hoozemans JJ; van Haastert ES; Eikelenboom P; de Vos RA; Rozemuller JM; Scheper W
    Biochem Biophys Res Commun; 2007 Mar; 354(3):707-11. PubMed ID: 17254549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies.
    Ferrer I; Blanco R; Carmona M; Puig B; Barrachina M; Gómez C; Ambrosio S
    J Neural Transm (Vienna); 2001; 108(12):1383-96. PubMed ID: 11810403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rescue of α-synuclein aggregation in Parkinson's patient neurons by synergistic enhancement of ER proteostasis and protein trafficking.
    Stojkovska I; Wani WY; Zunke F; Belur NR; Pavlenko EA; Mwenda N; Sharma K; Francelle L; Mazzulli JR
    Neuron; 2022 Feb; 110(3):436-451.e11. PubMed ID: 34793693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease.
    Vitte J; Traver S; Maués De Paula A; Lesage S; Rovelli G; Corti O; Duyckaerts C; Brice A
    J Neuropathol Exp Neurol; 2010 Sep; 69(9):959-72. PubMed ID: 20720502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of endoplasmic reticulum stress defined by activated unfolded protein response in multiple system atrophy.
    Makioka K; Yamazaki T; Fujita Y; Takatama M; Nakazato Y; Okamoto K
    J Neurol Sci; 2010 Oct; 297(1-2):60-5. PubMed ID: 20667553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain.
    Roberts RF; Wade-Martins R; Alegre-Abarrategui J
    Brain; 2015 Jun; 138(Pt 6):1642-57. PubMed ID: 25732184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxic properties of microsome-associated alpha-synuclein species in mouse primary neurons.
    Colla E; Panattoni G; Ricci A; Rizzi C; Rota L; Carucci N; Valvano V; Gobbo F; Capsoni S; Lee MK; Cattaneo A
    Neurobiol Dis; 2018 Mar; 111():36-47. PubMed ID: 29246724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue transglutaminase-catalysed cross-linking induces Apolipoprotein E multimers inhibiting Apolipoprotein E's protective effects towards amyloid-beta-induced toxicity.
    de Jager M; Drukarch B; Hofstee M; Brevé J; Jongenelen CA; Bol JG; Wilhelmus MM
    J Neurochem; 2015 Sep; 134(6):1116-28. PubMed ID: 26088696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered machinery of protein synthesis is region- and stage-dependent and is associated with α-synuclein oligomers in Parkinson's disease.
    Garcia-Esparcia P; Hernández-Ortega K; Koneti A; Gil L; Delgado-Morales R; Castaño E; Carmona M; Ferrer I
    Acta Neuropathol Commun; 2015 Dec; 3():76. PubMed ID: 26621506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease.
    Ferrer I; Martinez A; Blanco R; Dalfó E; Carmona M
    J Neural Transm (Vienna); 2011 May; 118(5):821-39. PubMed ID: 20862500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue transglutaminase is not involved in the aggregate formation of stably expressed alpha-synuclein in SH-SY5Y human neuroblastoma cells.
    Suh MD; Park CH; Kim SS; Kil MO; Lee GH; Johnson GV; Chun W
    Arch Pharm Res; 2004 Aug; 27(8):850-6. PubMed ID: 15460447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease.
    Liu Z; Meray RK; Grammatopoulos TN; Fredenburg RA; Cookson MR; Liu Y; Logan T; Lansbury PT
    Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4635-40. PubMed ID: 19261853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gliadin peptides induce tissue transglutaminase activation and ER-stress through Ca2+ mobilization in Caco-2 cells.
    Caputo I; Secondo A; Lepretti M; Paolella G; Auricchio S; Barone MV; Esposito C
    PLoS One; 2012; 7(9):e45209. PubMed ID: 23049776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.